VITAMIN D TREATMENT OF PROSTATE CANCER

流行病学数据表明，维生素D可能在 前列腺癌的发病机制。此外，体外和动物研究 已经证明维生素D抑制前列腺癌细胞的生长。 本研究旨在检查 维生素D在治疗前列腺癌早期男性中的作用。男人 如果在初步治疗后， 前列腺癌（手术切除或放射治疗），他们 显示前列腺肿瘤标记物的血清水平升高， 前列腺特异性抗原（PSA）。他们一定是A期或B期 疾病和没有转移的证据，因此有最小的 复发性疾病研究的主要终点是显示 PSA水平上升速度减慢，作为前列腺速度减慢的指标 在维生素D治疗（骨化三醇，Rocaltrol-Roche）时的癌症生长。 到目前为止，本研究已招募了8名其他方面健康的男性。 1例受试者在开始治疗前被排除，原因是 鉴定潜在转移性疾病。七个科目有 开始接受骨化三醇治疗两名受试者退出 肾结石的症状有哪些？一例受试者 退出研究，因为他的医生开始使用雄激素 消融治疗，尽管没有癌症的客观证据 这个人的进步。所有7例受试者均显示出有益的 对治疗的反应，与PSA升高速率相比， 与治疗开始前的上升率相当。

Epidemiologic data suggest that vitamin D may play a role in the pathogenesis of prostate cancer. Moreover, in vitro and animal studies have shown that vitamin D inhibits the growth of prostate cancer cells. This study was designed to examine the potential clinical utility of vitamin D in treating men with early stages of prostate cancer. Men were enrolled into this study if, after primary treatment of their prostate cancer (surgical prostatectomy or radiation therapy), they demonstrated a rising serum level of the prostate tumor marker, Prostatic Specific Antigen (PSA). They must have had stage A or B disease and not have evidence of metastasis, and therefore have minimal recurrent disease. The primary endpoint of the study is to show a slowing of the rate of rise of PSA levels as an index of slowed prostate cancer growth while on vitamin D therapy (calcitriol, Rocaltrol-Roche). Eight otherwise healthy men have thus far been enrolled in this study. One subject was excluded prior to the initiation of therapy due to the identification of potential metastatic disease. Seven subjects have been initiated on calcitriol therapy. Two subjects were withdrawn from therapy due to the development of kidney stones. One subject was withdrawn from the study because his physician initiated androgen ablation therapy, although there was no objective evidence of cancer progression in this individual. All 7 subjects have shown a beneficial response to the therapy, with a slowing of the PSA rate of rise compared to the rate of rise before therapy was initiated.